# Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/Refractory Malignancies

> **NCT07730125** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **CoRegen, Inc.** · enrollment: 67 (estimated)

## Conditions studied

- HR-positive, HER2-negative Breast Cancer
- TNBC - Triple-Negative Breast Cancer
- Prostate Cancer

## Interventions

- **DRUG:** CRG-150

## Key facts

- **NCT ID:** NCT07730125
- **Lead sponsor:** CoRegen, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-11
- **Primary completion:** 2029-06
- **Final completion:** 2030-06
- **Target enrollment:** 67 (ESTIMATED)
- **Last updated:** 2026-10-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07730125

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07730125, "Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/Refractory Malignancies". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07730125. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*